These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2324766)

  • 1. Giant axonal neuropathy: studies with sulfhydryl donor compounds.
    Tandan R; Bradley WG; Fillyaw MJ
    J Neurol Sci; 1990 Feb; 95(2):153-62. PubMed ID: 2324766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggregation of a subpopulation of vimentin filaments in cultured human skin fibroblasts derived from patients with giant axonal neuropathy.
    Bousquet O; Basseville M; Vila-Porcile E; Billette de Villemeur T; Hauw JJ; Landrieu P; Portier MM
    Cell Motil Cytoskeleton; 1996; 33(2):115-29. PubMed ID: 8635201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neurotoxins 2,5-hexanedione and acrylamide promote aggregation of intermediate filaments in cultured fibroblasts.
    Durham HD; Pena SD; Carpenter S
    Muscle Nerve; 1983; 6(9):631-7. PubMed ID: 6361548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermediate filament aggregation in fibroblasts of giant axonal neuropathy patients is aggravated in non dividing cells and by microtubule destabilization.
    Bomont P; Koenig M
    Hum Mol Genet; 2003 Apr; 12(8):813-22. PubMed ID: 12668605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal intermediate filament organization alters mitochondrial motility in giant axonal neuropathy fibroblasts.
    Lowery J; Jain N; Kuczmarski ER; Mahammad S; Goldman A; Gelfand VI; Opal P; Goldman RD
    Mol Biol Cell; 2016 Feb; 27(4):608-16. PubMed ID: 26700320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunocytochemical studies of intermediate filament aggregates and their relationship to microtubules in cultured skin fibroblasts from patients with giant axonal neuropathy.
    Pena SD; Opas M; Turksen K; Kalnins VI; Carpenter S
    Eur J Cell Biol; 1983 Sep; 31(2):227-34. PubMed ID: 6315439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that formation of an intermediate filament-protein complex plays a primary role in aggregation of neurofilaments, glial fibrillary acidic protein (GFAP)-filaments and vimentin-filaments by 2,5-hexanedione.
    Durham HD; Salera I; Dahrouge S
    J Neuropathol Exp Neurol; 1989 Mar; 48(2):197-211. PubMed ID: 2466109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Childhood giant axonal neuropathy. Case report and review of the literature.
    Tandan R; Little BW; Emery ES; Good PS; Pendlebury WW; Bradley WG
    J Neurol Sci; 1987 Dec; 82(1-3):205-28. PubMed ID: 2831308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the intermediate filament apparatus in skin fibroblasts from patients with giant axonal neuropathy: effect of trypsin.
    Manetti R; Ceccarini C; Guazzi G; Federico A; Tiezzi A; Bugnoli M; Ceccarini EC
    Cell Motil Cytoskeleton; 1987; 8(1):55-60. PubMed ID: 3308126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of giant axonal neuropathy showing focal aggregation and hypophosphorylation of intermediate filaments.
    Mohri I; Taniike M; Yoshikawa H; Higashiyama M; Itami S; Okada S
    Brain Dev; 1998 Dec; 20(8):594-7. PubMed ID: 9865543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy.
    Mussche S; Devreese B; Nagabhushan Kalburgi S; Bachaboina L; Fox JC; Shih HJ; Van Coster R; Samulski RJ; Gray SJ
    Hum Gene Ther; 2013 Feb; 24(2):209-19. PubMed ID: 23316953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormalities of the axonal cytoskeleton in giant axonal neuropathy.
    Donaghy M; King RH; Thomas PK; Workman JM
    J Neurocytol; 1988 Apr; 17(2):197-208. PubMed ID: 3204412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Giant axonal neuropathy: an inborn error of organization of intermediate filaments.
    Pena SD
    Muscle Nerve; 1982 Feb; 5(2):166-72. PubMed ID: 6280044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calpain-mediated proteolysis of vimentin filaments is augmented in giant axonal neuropathy fibroblasts exposed to hypotonic stress.
    Phillips CL; Fu D; Herring LE; Armao D; Snider NT
    Front Cell Dev Biol; 2022; 10():1008542. PubMed ID: 36393840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Giant axonal neuropathy: intermediate filament disease with involvement of the peripheral and central nervous system].
    Buissonnière RF; Routon MC; Robain O; Ponsot G; Arthuis M
    Rev Neurol (Paris); 1989; 145(5):355-61. PubMed ID: 2662338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Giant axonal neuropathy: report of two siblings with endocrinological and histological studies.
    Takebe Y; Koide N; Takahashi G
    Neuropediatrics; 1981 Nov; 12(4):392-404. PubMed ID: 6801537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in lipid metabolism gene expression and abnormal lipid accumulation in fibroblast explants from giant axonal neuropathy patients.
    Leung CL; Pang Y; Shu C; Goryunov D; Liem RK
    BMC Genet; 2007 Mar; 8():6. PubMed ID: 17331252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrastructural studies of the dying-back process. IV. Differential vulnerability of PNS and CNS fibers in experimental central-peripheral distal axonopathies.
    Spencer PS; Schaumburg HH
    J Neuropathol Exp Neurol; 1977; 36(2):300-20. PubMed ID: 190358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Giant axonal neuropathy. A neuropathological study.
    Kretzschmar HA; Berg BO; Davis RL
    Acta Neuropathol; 1987; 73(2):138-44. PubMed ID: 3604581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Explaining intermediate filament accumulation in giant axonal neuropathy.
    Opal P; Goldman RD
    Rare Dis; 2013; 1():e25378. PubMed ID: 25003002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.